Our blog
Measuring molecular interactions in solution or on a surface
There are several ways to categorise affinity assays. For example, binding can be measured in solution or on an immobilised ligand. And you might be pondering which is the right method for your needs and experimental conditions. The decision on whether measuring binding affinity in solution or on a surface should be weighed against advantages and disadvantages. We have summarised them here for you.
April 21, 2022
Quo Vadis technology – the future of affinity measurements
We asked three biophysics experts to share their thoughts on the current challenges and future expectations of analytical instruments. Let’s take a leap into the future with them.
March 29, 2022
Getting to know HexagonFab co-founder and biosensing expert Ruizhi Wang
“We have the opportunity to radically change how novel medicines are developed.” - Ruizhi Wang talks about his experience as a tech founder: from how HexagonFab was born to what his workdays look like. Spoiler: it’s all about the team!
December 2, 2021
Looking for the Achilles heel of breast cancer
Breast cancer is the second cause of mortality among women around the world and the most common type of cancer in the UK. Despite recent advances in treatments, survival varies among patients, and efforts must continue to find new detection strategies and treatments for this disease. 
October 29, 2021
HexagonFab wins SLAS top startup award
At ELRIG Drug Discovery 2021, HexagonFab received the Innovation AveNEW top startup company award from SLAS!
October 20, 2021
Detecting pollutants in environmental and food samples
Contamination with antibiotics pose a serious global threat. Low concentrations of pollutants found in water are also known to cause significant health and environment problems. These include different types of small molecules: sensitive analytical instruments with low detection limits are thus essential…
October 5, 2021
Accelerating COVID-19 research with rapid binding studies
The pandemic has catalysed faster pharmaceutical processes. Studies on SARS-CoV-2 receptor binding mechanisms allowed the design and implementation of therapeutic strategies to block the virus and boost immunity. However, there are still a lot of unanswered questions, particularly concerning virus variants.
September 15, 2021
Three things customers keep telling us
Biomolecular interactions are the beating heart of biology: critical for both fundamental research and drug discovery. Yet, assessing the performance of protein binders can be time-consuming and expensive. 
July 29, 2021
HexagonFab needs your help!
All you need to do: fill in a 3-minute user experience survey before July 30
July 9, 2021
HexagonFab named one of the best Cambridge based biotechnology startups and companies to work for
We are very proud to be recognized among this leading group of companies!
June 17, 2021
HexagonFab secures £1.9m (USD 2.6m) seed funding to launch the Bolt
HexagonFab today announces a £1.9 million (CHF 2.5 million) seed funding round, led by Cambridge Enterprise, joined by Parkwalk, New Grounds VC, Silicon Valley based R42 Group, Swiss Health Angels and several private investors.
April 20, 2021
2020 Venture Finalist
Lockdown does not mean slowdown. HexagonFab has just been announced as one of the 2020 Venture Finalists. The team will be presenting their solution to a panel of industry experts and investors.
May 1, 2020
COVID-19 update
"Couldn't HexagonFab's sensor help in the current scramble for COVID-19 tests?" Many of you have reached out to us in the past weeks whether we could help with an innovative test solution as response to the SARS-COV-2 virus - something that has also been of great interest to us.‍ We are in discussions with several manufacturers and research groups to develop & deploy a rapid field-testing solution.
April 3, 2020
Customer trials ongoing
Our evaluation kits were completed at the beginning of the year - in the past weeks the team has been extremely busy meeting with users & customers at conferences and on-site to introduce HexagonFab Bolt kit. Many users have expressed interest to use the kit for their drug discovery and bioprocess monitoring projects.
March 12, 2020
HexagonFab wins AMS Corporate Challenge on Next Generation Medical Sensing
Last week we presented our solution for next generation medical sensing to a panel of experts at AMS, a world-leader in automotive, wearable and medical sensing.
February 5, 2020
AMS' Corporate Challenge in Graz
HexagonFab was invited to be a presenting company at AMS Corporate Challenge at the 2020 Health Tech Hub in Graz.
January 16, 2020
Evaluation kits finished and ready for testing
The new prototype can analyse biomolecular interactions (proteins & small molecules) with a graphene biosensor paired with a simple electronic reader. 
December 9, 2019
Trip to Boston
HexagonFab invited to Boston by InnovateUK as part of a graphene delegation
November 20, 2019
Graphene invited HexagonFab to Health Investment Forum
HexagonFab will be attending the Graphene Flagship's health investment forum "Graphene connect" in Barcelona on November 6th 2019
October 8, 2019
ELRIG - Drug Discovery 2019
Between Nov 5-6th ELRIG will be hosting its next Drug Discovery conference at which HexagonFab will be attending.
October 1, 2019
Ruizhi Wang awarded prestigous fellowship by Royal Academy of Engineering
Dr. Ruizhi Wang has been awarded a Royal Academy of Engineering Enterprise Fellowship
July 4, 2019
Royal Society Awards "Emerging Technology Prize" to HexagonFab
The focus of the event was the Royal Society of Chemistry Emerging Technologies Competition final, in which 39 candidates – from a mixture of start-ups, SMEs and university research spin-outs – pitched their ideas to panels of experts in a ‘Dragon’s Den’ style competition.
October 18, 2018
Merck awards HexagonFab's technology the "Displaying Futures Award"
HexagonFab wins Merck's Displaying Futures Award 2018
June 12, 2018